Pharmaceutical Executive Issue Alert Having trouble viewing this email? Click here
Web Version | Share with a colleague | View Digital Edition | Subscribe
In our September issue of Pharmaceutical Executive
FEATURES
Cover Story
 Pharm Exec's 14th Annual Industry Audit
Bill Trombetta
After a sharp spike in revenues, this year's audit finds our 25 companies doubling down to secure the operational efficiencies that promise to better align with an increasingly tightfisted payer community. Never before has market relevance been so firmly linked to customer reputation.
From the Editor
Audit Alliterations
William Looney
A closer look at our Industry Audit numbers hints to a clear divide between two alternative strategies for long-term growth: scale versus focus.
Global
 China: Present for the Journey
 Jonathan Zhu
Tighter public scrutiny combined with tough new standards for clinical testing and the regulatory approval of foreign medicines are clouding future revenue projections for multinational drug makers in China. But they also represent an opportunity.
Interview
 Biotech Positioning for Boom Times and Beyond
 William Looney
With indications that the long bubble in biotech valuations may be primed for adjustment, Pharm Exec sat down with one of the investment community's leading biotech strategists, Tony Gibney, Managing Partner of Leerink Partners LLC, to better understand today's state of play in this critically innovative segment of the life sciences industry.
R&D
 ‘Systems’ Spark Sought for Clinical Trials
 Casey McDonald
Amid growing calls for more industry alignment on clinical trials, the Alliance for Clinical Research Excellence and Safety (ACRES) is prioritizing a “systems” approach to trial management. Reevaluating and standardizing the building blocks of high performing trial sites is a key first step.
ALSO IN THIS ISSUE
 Syncing Personalized Medicine and Marketing
Matt Wallach
The new generation of individualized treatments will require life sciences companies to evolve how they reach and educate the healthcare community. Are your commercial operations up to the task?

 Europe's Convergence Chasm on Drug Regulation
Reflector
France is a striking example of why the EU is still only "edging towards" a genuine universal system.

Whither Off-Label Communications Policy?
Jill Wechsler
Amarin ruling puts pressure on FDA to reassess marketing rules.
 
WEBCASTS
New expensive treatments for hepatitis C infection: have US payers reached a tipping point?
Establishing Processes and Controls to Ensure an Inspection-ready TMF Every Day
Engineer Your Business to Win in the Mobile Selling Moment
 
Download the
issue:
 
image

Pharmaceutical Executive is free to qualified subscribers. To subscribe, click here.

Click here to contact the Pharmaceutical Executive sales team.
Twitter LinkedIn